Cancer types · Other solid tumours
Bladder & Urothelial Cancers
Urothelial cancers most often arise in the bladder but can also occur in the upper urinary tract (renal pelvis and ureter). Whether the disease is non-muscle-invasive, muscle-invasive or metastatic shapes every discussion.
In advanced disease, FGFR alterations and other biomarkers may be discussed.
Clinical and molecular questions that often arise
- Is the cancer non-muscle-invasive, muscle-invasive or metastatic?
- For advanced disease, has FGFR testing been done?
- For upper-tract disease, should Lynch syndrome be considered?
- Are there trials relevant to the stage and molecular profile?
Information that may be part of an individual assessment
- Cystoscopy and resection (TURBT) with histopathology.
- Urine cytology and imaging.
- Molecular testing in advanced disease.
Which investigations are appropriate is decided by the treating team for each person.
Molecular profiling and biomarker interpretation
Depending on the setting, molecular and biomarker questions in bladder & urothelial cancers may involve:
- FGFR3 and FGFR2 alterations
- PD-L1 in selected settings
- HER2 expression
- MSI-high or MMR-deficient status (particularly in upper-tract disease)
Biomarkers, panels and available tests vary by subtype, disease setting, assay and guideline version. A detected alteration is not automatically actionable.
How KPCIRC pathways may apply
POAS
POAS may help interpret a report in advanced urothelial cancer and set out evidence and trial questions for FGFR and other alterations.
Molecular Tumour Board
MTB discussion may help with bladder-preservation questions or complex staging.
Second opinion and progression review
A second opinion may help clarify the choice between surgery and bladder-preserving approaches. Progression review can organise recurrence findings.
Hereditary risk and screening
Upper-tract urothelial cancer is associated with Lynch syndrome. MMR testing and a family history review may prompt genetics assessment.
How to access the relevant pathway
Patients and families
- Talk to your treating oncologist about whether an additional review may help.
- Request a consultation and tell us which question you want answered.
- Share records only when asked, through the secure route.
Referring doctors
- Define the clinical question and the pathway: POAS, MTB, second opinion or progression review.
- Start a case enquiry without patient identifiers.
- Scope, fees and timing are confirmed before any review proceeds.
Questions and limitations
Why does muscle invasion matter?
It is a key dividing line that changes the questions and treatment approaches discussed.
Is bladder cancer inherited?
Usually not, although upper-tract urothelial cancer can be linked to Lynch syndrome.
Does this page apply to my situation?
This page is educational. It explains common questions but cannot account for individual circumstances. Your treating clinician is best placed to interpret your reports and plan your care.
Educational content reviewed against the KPCIRC service scope. It is not a diagnosis, a treatment recommendation or a statement that a specialist or service is available for this cancer type.